Baker BROS. Advisors LP Takes Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Baker BROS. Advisors LP purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 644,116 shares of the company's stock, valued at approximately $7,510,000. Baker BROS. Advisors LP owned 0.63% of Intellia Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. increased its position in Intellia Therapeutics by 125.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company's stock worth $1,411,000 after buying an additional 67,276 shares in the last quarter. Avanza Fonder AB purchased a new stake in shares of Intellia Therapeutics during the 4th quarter worth $421,000. Barclays PLC increased its holdings in shares of Intellia Therapeutics by 17.7% during the third quarter. Barclays PLC now owns 292,795 shares of the company's stock valued at $6,017,000 after acquiring an additional 44,022 shares in the last quarter. ARK Investment Management LLC grew its position in Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after purchasing an additional 280,946 shares during the period. Finally, SG Americas Securities LLC grew its holdings in Intellia Therapeutics by 85.7% in the fourth quarter. SG Americas Securities LLC now owns 44,838 shares of the company's stock valued at $523,000 after purchasing an additional 20,694 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA traded down $0.12 on Friday, hitting $8.16. The company's stock had a trading volume of 2,969,427 shares, compared to its average volume of 2,471,132. The company has a 50-day simple moving average of $8.15 and a 200 day simple moving average of $11.15. The company has a market capitalization of $845.24 million, a PE ratio of -1.50 and a beta of 2.33. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. The company had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. During the same period last year, the business posted ($1.12) earnings per share. The firm's quarterly revenue was down 42.6% compared to the same quarter last year. On average, equities research analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NTLA has been the subject of several analyst reports. Citigroup dropped their price target on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research note on Friday. Wells Fargo & Company reduced their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. HC Wainwright initiated coverage on shares of Intellia Therapeutics in a research note on Wednesday, March 5th. They set a "buy" rating and a $30.00 price target for the company. The Goldman Sachs Group reiterated a "sell" rating and issued a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. Finally, Wolfe Research upgraded Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective for the company in a research report on Monday, April 21st. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $36.47.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.